HC Wainwright Estimates Indivior’s Q1 Earnings (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Indivior in a research note issued to investors on Monday, January 12th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of $0.72 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s FY2026 earnings at $3.00 EPS, FY2027 earnings at $3.21 EPS, FY2028 earnings at $3.35 EPS and FY2029 earnings at $3.56 EPS.

INDV has been the topic of a number of other research reports. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $41.00 price objective (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. Finally, Northland Securities set a $40.00 target price on shares of Indivior in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.57.

Indivior Stock Performance

Shares of INDV stock opened at $32.88 on Wednesday. The stock has a 50 day moving average price of $34.32 and a 200 day moving average price of $26.43. Indivior has a 52-week low of $7.62 and a 52-week high of $38.00. The firm has a market capitalization of $4.11 billion, a P/E ratio of 35.74 and a beta of 0.75.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.34. The business had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%.

Hedge Funds Weigh In On Indivior

A number of large investors have recently bought and sold shares of INDV. Allspring Global Investments Holdings LLC bought a new stake in Indivior during the 4th quarter valued at $448,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Indivior by 43.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock worth $11,395,000 after purchasing an additional 96,177 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Indivior by 752.2% during the 4th quarter. SG Americas Securities LLC now owns 412,197 shares of the company’s stock worth $14,790,000 after purchasing an additional 363,829 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Indivior during the fourth quarter valued at about $312,000. Finally, GAMMA Investing LLC grew its stake in Indivior by 544.6% in the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

Insider Buying and Selling

In other Indivior news, Director Daniel A. Ninivaggi purchased 775 shares of the stock in a transaction dated Monday, January 5th. The stock was purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. This trade represents a 4.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David E. Wheadon acquired 1,771 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the purchase, the director owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. This represents a 14.03% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 4,871 shares of company stock valued at $172,385 over the last quarter.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.